Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1992 Feb;30(2):296–299. doi: 10.1128/jcm.30.2.296-299.1992

Sensitivity and specificity of a recombinant transmembrane glycoprotein (rgp21)-spiked western immunoblot for serological confirmation of human T-cell lymphotropic virus type I and type II infections.

R B Lal 1, S Brodine 1, J Kazura 1, E Mbidde-Katonga 1, R Yanagihara 1, C Roberts 1
PMCID: PMC265049  PMID: 1347047

Abstract

Serum specimens (n = 2,712) obtained from individuals residing in diverse geographic regions and categorized as seropositive (n = 122), seroindeterminate (n = 523), or seronegative (n = 2,067) for human T-cell lymphotropic virus (HTLV) infection in accordance with U.S. Public Health Service guidelines were retested by recombinant transmembrane protein (rgp21)-spiked Western immunoblotting. Of the 122 HTLV-positive specimens, those from 85 of 85 (100%) U.S. blood donors, 2 of 2 (100%) Brazilians, 1 of 2 (50%) Indonesians, 14 of 14 (100%) Solomon Islanders, and 18 of 19 (95%) Papua New Guineans reacted with rgp21, yielding an overall sensitivity of 98% (120 of 122). Specimens from individuals whose infections were confirmed to be HTLV type I or HTLV type II by the polymerase chain reaction assay reacted equally well with rgp21. Of the 523 HTLV-indeterminate specimens, those from 21 of 379 (5.5%) U.S. blood donors, 3 of 6 (50%) Brazilians, 10 of 23 (44%) Ugandans, 8 of 49 (16%) Indonesians, 4 of 36 (11%) Solomon Islanders, and 5 of 30 (17%) Papua New Guineans reacted with rgp21. None of these 51 specimens reacted with native gp46 and/or gp61/68 in a radioimmunoprecipitation assay, suggesting a false-positive reaction (9.75%). Of the 2,067 HTLV-negative specimens, 12 reacted with rgp21, yielding a false-positivity rate of 0.6%. These data indicate that while detection of rgp21 is highly sensitive, it can yield false-positive results. Thus, specimens exhibiting reactivity with rgp21 in the absence of reactivity with native gp46 and/or gp61/68 by Western blot should be tested further by a radioimmunoprecipitation assay to verify HTLV type I or type II infection.

Full text

PDF
296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. W., Epstein J. S., Lee T. H., Lairmore M. D., Saxinger C., Kalyanaraman V. S., Slamon D., Parks W., Poiesz B. J., Pierik L. T. Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors. Blood. 1989 Nov 15;74(7):2585–2591. [PubMed] [Google Scholar]
  2. Chen Y. M., Lee T. H., Samuel K. P., Okayama A., Tachibana N., Miyoshi I., Papas T. S., Essex M. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. J Virol. 1989 Nov;63(11):4952–4957. doi: 10.1128/jvi.63.11.4952-4957.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coates S. R., Harris A. J., Parkes D. L., Smith C. M., Liu H. L., Akita R. W., Ferrer M. M., Sampson E. K., Brandis J. W., Sliwkowski M. X. Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins. J Clin Microbiol. 1990 Jun;28(6):1139–1142. doi: 10.1128/jcm.28.6.1139-1142.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hartley T. M., Khabbaz R. F., Cannon R. O., Kaplan J. E., Lairmore M. D. Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays. J Clin Microbiol. 1990 Apr;28(4):646–650. doi: 10.1128/jcm.28.4.646-650.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hartley T. M., Malone G. E., Khabbaz R. F., Lal R. B., Kaplan J. E. Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms. J Clin Microbiol. 1991 Jun;29(6):1125–1127. doi: 10.1128/jcm.29.6.1125-1127.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Haseltine W. A., Sodroski J. G., Patarca R. Structure and function of the genome of HTLV. Curr Top Microbiol Immunol. 1985;115:177–209. doi: 10.1007/978-3-642-70113-9_12. [DOI] [PubMed] [Google Scholar]
  7. Kwok S., Kellogg D., Ehrlich G., Poiesz B., Bhagavati S., Sninsky J. J. Characterization of a sequence of human T cell leukemia virus type I from a patient with chronic progressive myelopathy. J Infect Dis. 1988 Dec;158(6):1193–1197. doi: 10.1093/infdis/158.6.1193. [DOI] [PubMed] [Google Scholar]
  8. Lee H., Swanson P., Shorty V. S., Zack J. A., Rosenblatt J. D., Chen I. S. High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science. 1989 Apr 28;244(4903):471–475. doi: 10.1126/science.2655084. [DOI] [PubMed] [Google Scholar]
  9. Lillehoj E. P., Alexander S. S., Dubrule C. J., Wiktor S., Adams R., Tai C. C., Manns A., Blattner W. A. Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide. J Clin Microbiol. 1990 Dec;28(12):2653–2658. doi: 10.1128/jcm.28.12.2653-2658.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipka J. J., Bui K., Reyes G. R., Moeckli R., Wiktor S. Z., Blattner W. A., Murphy E. L., Shaw G. M., Hanson C. V., Sninsky J. J. Determination of a unique and immunodominant epitope of human T cell lymphotropic virus type I. J Infect Dis. 1990 Aug;162(2):353–357. doi: 10.1093/infdis/162.2.353. [DOI] [PubMed] [Google Scholar]
  11. Manns A., Blattner W. A. The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease. Transfusion. 1991 Jan;31(1):67–75. doi: 10.1046/j.1537-2995.1991.31191096189.x. [DOI] [PubMed] [Google Scholar]
  12. Manns A., Murphy E. L., Wilks R., Haynes G., Figueroa J. P., Hanchard B., Barnett M., Drummond J., Waters D., Cerney M. Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood. 1991 Feb 15;77(4):896–905. [PubMed] [Google Scholar]
  13. Mitani M., Cianciolo G. J., Snyderman R., Yasuda M., Good R. A., Day N. K. Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses. Proc Natl Acad Sci U S A. 1987 Jan;84(1):237–240. doi: 10.1073/pnas.84.1.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nyunoya H., Ogura T., Kikuchi M., Iwamoto H., Yamashita K., Maekawa M., Takebe Y., Miyamura K., Yamazaki S., Shimotohno K. Expression of HTLV-I envelope protein fused to hydrophobic amino-terminal peptide of baculovirus polyhedrin in insect cells and its application for serological assays. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1311–1321. doi: 10.1089/aid.1990.6.1311. [DOI] [PubMed] [Google Scholar]
  15. Ruegg C. L., Monell C. R., Strand M. Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II. J Virol. 1989 Aug;63(8):3250–3256. doi: 10.1128/jvi.63.8.3250-3256.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Samuel K. P., Lautenberger J. A., Jorcyk C. L., Josephs S., Wong-Staal F., Papas T. S. Diagnostic potential for human malignancies of bacterially produced HTLV-I envelope protein. Science. 1984 Nov 30;226(4678):1094–1097. doi: 10.1126/science.6208612. [DOI] [PubMed] [Google Scholar]
  17. Sandler S. G., Fang C., Williams A. Retroviral infections transmitted by blood transfusion. Yale J Biol Med. 1990 Sep-Oct;63(5):353–360. [PMC free article] [PubMed] [Google Scholar]
  18. Williams A. E., Fang C. T., Slamon D. J., Poiesz B. J., Sandler S. G., Darr W. F., 2nd, Shulman G., McGowan E. I., Douglas D. K., Bowman R. J. Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science. 1988 Apr 29;240(4852):643–646. doi: 10.1126/science.2896386. [DOI] [PubMed] [Google Scholar]
  19. Yanagihara R., Nerukar V. R., Ajdukiewicz A. B. Comparison between strains of human T lymphotropic virus type I isolated from inhabitants of the Solomon Islands and Papua New Guinea. J Infect Dis. 1991 Sep;164(3):443–449. doi: 10.1093/infdis/164.3.443. [DOI] [PubMed] [Google Scholar]
  20. Yanagihara R., Nerurkar V. R., Garruto R. M., Miller M. A., Leon-Monzon M. E., Jenkins C. L., Sanders R. C., Liberski P. P., Alpers M. P., Gajdusek D. C. Characterization of a variant of human T-lymphotropic virus type I isolated from a healthy member of a remote, recently contacted group in Papua New Guinea. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1446–1450. doi: 10.1073/pnas.88.4.1446. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES